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Benefits of omalizumab on anxiety and depression in 
patients with severe asthma 
 
 
Abstract 
Background: Asthma is one of the most common chronic diseases and may cause 
psychiatric disorders affecting the patients’ quality of life. In our study, we evaluated the 
effect of omalizumab treatment on anxiety disorder and depression using Beck Depression 
Scale (BDS) and State Trait Anxiety Inventory (STAI). 
Methods: Anxiety level was determined with STAI, whereas depression level was 
evaluated by BDS. Patients were asked to mark the questionnaires to reflect their 
emotional state before treatment, and to reflect their emotions they are feeding in the 
current moment. All patients receiving omalizumab treatment were included in the study. 
Patients with known neuropsychiatric disorder were excluded from the study. 
Results: A total of 20 patients with mean age of 50.25 years were enrolled in the study. 
Gender distribution was: 5(25%) male patients and 15(75%) female patients.  All patients 
with severe asthma received omalizumab treatment. The omalizumab treatment period was 
shown for mean 17.6 months (2-40 months). In anxiety scales, there was statistically 
significant difference compared with pretreatment and posttreatment periods. Depression 
(moderate to severe) was present in 12 patients before omalizumab treatment and 3 
patients after omalizumab treatment. 
Conclusions: Uncontrolled asthma as a chronic disorder can cause depressive symptoms 
and worsen quality of life. We believe by controlling asthma, quality of life will improvein 
such patients. In appropriate indication, omalizumab can improve depression and anxiety 
in asthma patients. 
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Asthma is a major global health problem affecting over 300 million people of all 
ages worldwide and represents a significant socio-economic burden (1-3). It is stated in the 
literature that 5-10% of patients with asthma suffer from poorly-controlled disease despite 
corticosteroid treatment (4). It may cause psychiatric disorders via affecting the patients 
quality of life. Literature reports a significantly greater prevalence of mental disorders in 
people with asthma, with a particular emphasis on those with depression and/or anxiety (5-
7). Bronchial hyperactivation, airway obstruction and related cough and shortness of 
breath can be seen in case of exposure to any agents being susceptible. All these symptoms 
can be overcome with complete or partial treatment. Living with the sense of shortness of 
breath may also affect the psychological status of the patient. In patients with worse 
asthma control, anxiety and depression are seen more commonly than normal population 
(3-9). The effects of the disease on the physical, social and psychological functions can be 
evaluated by quality of life questionnaire. In our study, we evaluated the effect of 
omalizumab treatment on anxiety disorder and depression by Beck Depression Scale 
(BDS) and State Trait Anxiety Inventory (STAI). 
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Method 
This study was carried out between January-June 2015 in 
Antalya, Akdeniz University. In our study, we aimed to 
compare anxiety and depression status of severe asthma 
patients having omalizumab treatment with pretreatment 
period. For this purpose, the patients were asked to fill in the 
questionnaire.  
Anxiety level was determined with STAI, whereas 
depression level was evaluated by BDS. Patients were asked 
to mark the questionnaires to reflect their emotions they are 
feeling in the current moment. All patients having 
omalizumab treatment were included in the study. Patients 
with known neuropsychiatric disorder were excluded from 
the study.  
The study has been approved by the Ethics Committee of 
Akdeniz University.  
Assessment of the tests: 
Beck Depression Scale: BDS is a scale composed of 21 
questions and was developed for measuring emotional, 
cognitive and somatic motivation components. Also, BDS 
has been proven for Turkish population in matters of 
reliability and validity. In the scale, two questions provide 
emotional areas whereas five somatic signs, 11 cognitive 
functions, two behaviors and one question evaluate signs 
among people.  
The survey provides information about itself and widely 
used it in clinical practice and trials. Patients mark most 
suitable states for themselves. Each question is scored as 
0,1,2 or 3 and total scores are between 0 and 63. In 
assessment; 0-9 point shows minimal depression 10-18 mild, 
19-29 moderate and 30-63 severe (10).  
State Trait Anxiety Inventory: (STAI) is a self-assessing 
scale developed by Spielberger et al.  and is composed of 2 
scales of 20 questions (10). First part shows static anxiety 
and includes questions as ‘How do you feel now?’ Each 
question has four response options like; any, some, very 
much and completely. Second part of the test is composed of 
questions about continuous anxiety (For example; ‘mostly I 
feel good.’).  
The total score is between 20 and 80. Higher score 
indicates higher anxiety level. Turkish validation and 
reliability study was performed by Öner and Le Compte 
(12).  
Statistical analysis: The results are reported as the mean 
and categorical variables are given as percentages. The 
normality of distribution was confirmed by the Shapiro-
Wilk's W-test. Since Shapiro–Wilk's test results showed 
fitting to observed data against a normal distribution, 
statistical analysis of clinical data between two groups 
consisted of unpaired t-tests, whereas the chi-square/Fisher's 
exact tests were used for categorical variables.  
Analysis was performed using IBM SPSS statistics for 
Windows, Version 20.0 (IBM Corp. Released 2013. 
Armonk, NY: IBM Corp.) software and two-tailed p-value 
less than 0.05 was considered statistically significant. 
 
 
Results 
A total of 20 patients with mean age of 50.25 years were 
included in the study. Gender distribution was 5 (25%) male 
patients and 15(75%) female patients. All patients had severe 
asthma diagnosis and had omalizumab treatment. Period of 
omalizumab use was as mean 17.6 months (2-40 months). 
Before omalizumab treatment, asthma control level was poor 
in all patients.  
After omalizumab treatment, all patients’ asthma control 
levels improved in the level of good control of 70% 
comobidities, the most types were hypertension and diabetes 
mellitus, whereas, 14 patients had at least one comorbidity. 
In anxiety scales, there was statistically significant difference 
as compared with pretreatment and post treatment periods 
(table 1).  
 
Table 1. Comparison of anxiety scales of the patients 
before and after omalizumab treatment.  
 
 Pretreatment Posttreatment p-value 
Beck depression 
scale 
25.35 8.55 P<0.001 
Static scale 53.20 37.65 P<0.001 
Continuous scale 52.05 42.95 P<0.001 
 
Depression (moderate to severe) requires treatment 
which was present in 12 patients before omalizumab 
treatment, whereas there were three patients after 
omalizumab treatment (figure 1).  
Participants' static and continuous anxiety scores 
decreased significantly after omalizumab treatment 
compared with the scores before treatment. Except for one 
patient, every participant (95%) had been using inhalant 
bronchodilator therapy with montelukast before and after 
omalizumab treatment. 
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Figure 1. Beck Depression Scale of the patients before 
and after treatment 
 
Discussion 
Asthma is the most common chronic respiratory disease 
in the world. Good control of asthma is the first line aim of 
the treatment (13). If asthma is not controlled, it can cause 
depressive signs and worsens the quality of life. Most severe 
asthma patients show depressive and anxious signs (14-15).  
However, it is not clear that these signs worsen asthma 
severity or asthma causes these signs (16-17). In our study, 
severe asthma patients had omalizumab treatment in 
concordance with Global Initiative for Asthma (GINA) 
guidelines and the study revealed that anxiety and depression 
levels improved with symptom control and treatment.  
In literature, psychological disorders in asthma patients 
vary about 11% and 85% (18).  In a study with 406 asthma 
patients; in 34% participants, there was one or more 
psychiatric disorders. Mostly observed psychiatric disorders 
in such patients were stated as anxiety disorders. Most seen 
mood disorder was major depression (14, 16, 19). Katrz et al. 
performed a cohort study of 439 mostly female adult asthma 
patients and ofter observed depression, more than two times 
it compared with normal population. That study stated that 
worsening of asthma control is associated with depression 
(20).  From Brazil, Vieira et al. reported that the prevalence 
of psychiatric disorders in uncontrolled asthma patients is 
significantly higher. In such patients, besides controlling 
asthma, mood and effect must be examined (14). 
Asthma is a chronic disorder and in these patients 
because of chronic illness social isolation, self-limiting, 
characteristics and advanced age can cause depressive 
disorders. Severe asthma and depression can coexist often 
and both conditions show synergistic effect and can worsen 
the prognosis (21). Bozbaş et al. observed negative 
correlation between asthma control level and Beck 
Depression Scale score in their study. In the same study, it 
was stated that while treatment assessment of asthma 
patients; quality of life and psychological status must be 
evaluated as well (9). 
 In our study, all patients had severe asthma diagnosis 
and it was more often the female gender. Before omalizumab 
treatment, clinical significant depression was observed in 
60% (19) patients. After omalizumab treatment, there was no 
severe depression, whereas in 3 (1,5%) patients, we observed 
moderate depression. This observation shows that 
omalizumab treatment improves depression while 
controlling asthma. 
In literature, it was reported that while severity of chronic 
illnesses increases, prevalence of psychiatric disorders, 
anxiety, behavioral disorders also increase. Severe asthma 
patients claimed as being susceptible to anxiety disorders 
genetically (22). Anxiety was reported more often in late 
onset non- eosinophilic asthma phenotype (17). Giacco et al. 
reported that asthma patients had three times increased 
anxiety disorder risk during life (16). 
 In our study, both static and continuous anxiety scales 
were significantly higher before omalizumab treatment. 
Patients stated feeling better and enjoying more life after 
omalizumab treatment.  
In our study, montelukast as a predisposingt agent for 
depression was present in about all patients. Despite 
montelukast usage after controlling asthma depression, 
anxiety scale scores significantly  improved in our study. 
Most important limitation of our study is being retrospective 
and having insufficient pupliation. Despite these facts, our 
study has benefits because of its being the first study 
evaluating anxiety and depression in asthma patients with 
omalizumab treatment. 
In conclusion, uncontrolled asthma as a chronic disorder 
can cause depressive symptoms and worsen quality of life. 
We think that with asthma control the quality of life of such 
patients can improve. In appropriate indication, omalizumab 
treatment can improve depression and anxiety in asthma 
patients. 
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